Text Size

Biocompatibility and pharmacokinetic analysis of an intracameral polycaprolactone drug delivery implant for glaucoma

Kim J., Kudisch M., Mudumba S., Asada H., Aya-Shibuya E., Bhisitkul R.B., Desai T.A.


  • 2016
  • Investigative Ophthalmology and Visual Science
View publication
  • Therapeutic Area

    Glaucoma

  • Technology

    Drug Delivery

  • Affiliations

    San Francisco, CA, United States; Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, United States; Santen, Inc., Emeryville, CA, United States; Santen Pharmaceutical Co., Ltd., Nara RD Center, Nara, Japan; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, United States

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.


Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.


Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022